CoviVac (Russia COVID-19 vaccine)
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
|
CoviVac (Russian: КовиВак) is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Centre,[1] which is an institute of the Russian Academy of Sciences.[2] It was approved for use in Russia in February 2021, being the third COVID-19 vaccine to get approval in Russia.[1] It obtained a permission for phase III clinical trial on 2 June 2021.[3]
Technology[edit]
As an inactivated vaccine, CoviVac uses a more traditional technology that is similar to the inactivated polio vaccine. Initially, a sample of SARS-CoV-2 strain AYDAR-1 was isolated by the Chumakov Center at the Russian Academy of Sciences and used to grow large quantities of the virus using vero cells. From then on, the viruses are soaked in beta-propiolactone, which deactivates them by binding to their genes, while leaving other viral particles intact. The resulting inactivated viruses are then mixed with an aluminium-based adjuvant.[4]
Composition[edit]
One dose of 0.5 ml is composed only of 3 μg or more of SARS-CoV-2 strain AYDAR-1 antigen inactivated by beta-propiolactone and the following excipients:[5]
- 0.3–0.5 mg of aluminum hydroxide (adjuvant)
- 0.5 ml or less of phosphate buffer solution composed of disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, and water for injection
Usage[edit]
The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal fridge temperatures, of 2 to 8 degrees Celsius (35.6 to 46.4 Fahrenheit).[1]
Authorization[edit]
Full authorization
Emergency authorization |
On 20 February 2021, President Vladimir Putin announced that the vaccine was approved.[1]
References[edit]
- ^ a b c d Ivanova P (20 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Retrieved 13 March 2021.
- ^ Abbany Z (9 March 2021). "Two more Russian vaccines: What we do and don't know". Deutsche Welle. Retrieved 13 March 2021.
- ^ Реестр разрешений на проведение клинических исследований лекарственных средств. (in Russian), Catalogue of permissions for conducting clinical trials of pharmaceuticals, 2 June 2021, Minzdrav
- ^ Kozlovskaya L, Pinyaeva A, Kovpak A, Gordeichuk I, Volok V, Ignatiev G (1 April 2021). "«КОВИВАК»: инактивированный, но активный" ["COVIVAC": inactivated but active]. indicator.ru (Interview) (in Russian). Interviewed by Vodovozov A. Retrieved 19 May 2021.
- ^ "КовиВак (Вакцина коронавирусная инактивированная цельновирионная концентрированная очищенная)" [CoviVac (Inactivated whole-virion concentrated, purified coronavirus vaccine)]. vidal.ru (in Russian). 24 February 2021. Retrieved 19 May 2021.
External links[edit]
 |
Scholia has a profile for CoviVac (Q105597762). |
.svg){kind=small}
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |